Ben Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD
Show Description +
Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged? Editorially Independent content supported by Apellis.
Posted: 12/19/2024
Ben Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD
Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged? Editorially Independent content supported by Apellis.
Posted: 12/19/2024
New Retina Radio is forging forward with education, and they’re partnering with Vit Buckle Society to make it happen. Check out these quick-hit reviews of journal articles delivered by VBS members.
Switching from Aflibercept to Faricimab in Wet AMD Patients
Ben Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD
Please log in to leave a comment.